Immunotherapy News and Research RSS Feed - Immunotherapy News and Research

Immunotherapy is the concept of using the immune system to treat disease, for example, developing a vaccine against cancer. Immunotherapy may also refer to the therapy of diseases caused by the immune system, allergies for example.
Scientists combine immunotherapy with chemotherapy to eliminate cancer recurrence

Scientists combine immunotherapy with chemotherapy to eliminate cancer recurrence

Scientists from the United States have made an important step toward eliminating cancer recurrence by combining immunotherapy with chemotherapy. [More]
Experimental drug may become key tool to target triple-negative breast cancer with immunotherapy

Experimental drug may become key tool to target triple-negative breast cancer with immunotherapy

Previous studies at the University of Colorado Cancer Center show that the experimental drug AMPI-109 potently kills triple-negative breast cancer cells. [More]
New NCCN Imaging AUC released for eight new cancers

New NCCN Imaging AUC released for eight new cancers

The National Comprehensive Cancer Network, a Centers for Medicare & Medicaid Services-approved provider-led entity for imaging appropriate use criteria, continues to build its library of AUC and has published NCCN Imaging Appropriate Use Criteria for eight new cancer types. Launched in June 2016, NCCN Imaging AUC currently are available for 20 cancer types. [More]
Janssen seeks to extend DARZALEX license to benefit more multiple myeloma patients

Janssen seeks to extend DARZALEX license to benefit more multiple myeloma patients

Janssen-Cilag International NV has announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an immmunomodulatory agent) and dexamethasone, or bortezomib (a PI) and dexamethasone. [More]
Curbing immune system infighting could make treatment more effective for pancreatic cancer

Curbing immune system infighting could make treatment more effective for pancreatic cancer

Internal conflict between cell types explains why the immune system struggles to recognize and attack pancreatic cancer. [More]
Three like-minded nonprofits collaborate to launch immunotherapy clinical trial for pediatric brain tumors

Three like-minded nonprofits collaborate to launch immunotherapy clinical trial for pediatric brain tumors

A Kids' Brain Tumor Cure Foundation, Solving Kids' Cancer and the Ty Louis Campbell Foundation announce their joint financial support of a Phase 1 clinical trial to test the safety and efficacy of combination checkpoint inhibitors in the treatment of children with brain tumors. [More]
NIBIB researchers develop nanovaccine to enhance cancer immunotherapy

NIBIB researchers develop nanovaccine to enhance cancer immunotherapy

NIBIB researchers have created a nanovaccine that could make a current approach to cancer immunotherapy more effective while also reducing side effects. [More]
Stem cells derived from bone marrow provide better quality of life to transplant patients

Stem cells derived from bone marrow provide better quality of life to transplant patients

A large, nationwide study published in the journal JAMA Oncology found that people who received transplants of cells collected from a donor's bone marrow the original source for blood stem cell transplants, developed decades ago had better self-reported psychological well-being, experienced fewer symptoms of a common post-transplant side effect called graft-vs.-host disease and were more likely to be back at work five years after transplantation than those whose transplanted cells were taken from the donor's bloodstream. [More]
FDA grants Orphan Drug Designation to CD4CAR therapy for treatment of peripheral T-cell lymphoma

FDA grants Orphan Drug Designation to CD4CAR therapy for treatment of peripheral T-cell lymphoma

iCell Gene Therapeutics today (Aug. 11) announced that the Food and Drug Administration has granted Orphan Drug Designation for its chimeric antigen receptor engineered T-cells directed against the target protein CD4 (CD4CAR) for the treatment of peripheral T-cell lymphoma (PTCL). [More]
Analysis of biopsies during early treatment predicts patient’s response to melanoma immunotherapy

Analysis of biopsies during early treatment predicts patient’s response to melanoma immunotherapy

Immune response measured in tumor biopsies during the course of early treatment predicts which melanoma patients will benefit from specific immune checkpoint blockade drugs, researchers at The University of Texas MD Anderson Cancer Center report in the journal Cancer Discovery. [More]
Study finds oral immunotherapy safe, effective at suppressing peanut allergy in preschool children

Study finds oral immunotherapy safe, effective at suppressing peanut allergy in preschool children

Nearly 80 percent of peanut-allergic preschool children successfully incorporated peanut-containing foods into their diets after receiving peanut oral immunotherapy (OIT), a clinical trial has found. [More]
Researchers develop computational algorithm to analyze big genomic data for different cancers

Researchers develop computational algorithm to analyze big genomic data for different cancers

University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze "Big Data" obtained from tumor samples to better understand and treat cancer. [More]
CTCA at Western begins clinical trial for novel antibody to treat patients with advanced tumors

CTCA at Western begins clinical trial for novel antibody to treat patients with advanced tumors

Cancer Treatment Centers of America at Western Regional Medical Center has dosed its first three patients as part of the launch of a Phase I clinical trial using a novel antibody to treat patients with advanced solid tumors. [More]
Immunotherapy innovations in oncology: an interview with Robert LaCaze

Immunotherapy innovations in oncology: an interview with Robert LaCaze

The body’s immune system is an excellent weapon against many diseases. For more than 100 years, immunology and immunotherapy have played an ever-increasing role in the understanding and treatment of cancer. [More]
Oncolytic virotherapy medicine shows positive treatment outcomes in late-stage cancer patients

Oncolytic virotherapy medicine shows positive treatment outcomes in late-stage cancer patients

The surprisingly positive treatment outcomes using Rigvir virotherapy for late stages cancer patients were recently published. [More]
Wistar scientists discover marker for PMN-MDSCs in the blood of cancer patients

Wistar scientists discover marker for PMN-MDSCs in the blood of cancer patients

Myeloid-derived suppressor cells (MDSCs) are a population of immune cells that have been implicated in tumor resistance to various types of cancer treatment, including targeted therapies, chemotherapy and immunotherapy. [More]
Experimental immunotherapeutic strategy may pave way for new treatments against lymphoma

Experimental immunotherapeutic strategy may pave way for new treatments against lymphoma

Lymphoma is a cancer that affects lymphocytes, a type of white blood cell. The disease originates in a lymphoid organ (lymph node, spleen, or bone marrow) before spreading through the blood to infiltrate not only other lymphoid organs but also other tissues. [More]
Watch-and-wait approach may prove successful in subset of adults with advanced kidney cancer

Watch-and-wait approach may prove successful in subset of adults with advanced kidney cancer

Watch-and-wait approach means some patients could delay taking highly toxic non-curative anticancer drugs that come with substantial side effects [More]
PD-1-responsive T cells may offer clues to design more effective drugs for cancer

PD-1-responsive T cells may offer clues to design more effective drugs for cancer

Cancer immunotherapy drugs that block the inhibitory PD-1 pathway have shown success in clinical trials and are now FDA-approved for melanoma, lung cancer and bladder cancer. Yet many patients' tumors do not respond to these drugs. [More]
Metabolic-checkpoint inhibitor combination approach may improve cancer therapies

Metabolic-checkpoint inhibitor combination approach may improve cancer therapies

Reprogramming of the molecular pathways underlying normal metabolism is essential for T cell infection-fighting function and for the immune system to form a "memory" of the microbes it has already encountered. But exactly how metabolism in exhausted T cells is maintained in chronic infections and cancer is a missing element in this line of research. [More]
Advertisement
Advertisement